Investigating stromal vascular fraction therapy for COVID-19
San Diego Academy of Regenerative Therapies publishes article about first-in-human clinical trial using adipose-derived SVF to treat post-COVID-19 patients suffering lung damage
SAN DIEGO—A member of the faculty at San Diego Academy of Regenerative Therapies (SDARTs) has published a paper addressing pulmonary and respiratory therapies for patients who have suffered from the SARS-CoV-2 Coronavirus. The article, entitled “Potential Use of Cellular Stromal Vascular Fraction in Post-COVID-19 Pulmonary Injury and Adult Respiratory Distress,” was written by Robert W. Alexander, M.D., DMD, FICS, the principal investigator for the first-in-human clinical trial.
The paper reviews many of the current issues facing survivors of moderate to severe COVID-19 infections, and explores options for a new therapeutic approach — which shows promise to reverse some residual damage to the lung and gas exchange functions. The article hypothesizes that reducing the widespread pulmonary inflammatory and immune responses of COVID-19 with stromal vascular fraction (SVF) treatment may reduce the residual damage the disease can cause.
“This damage represents a reasonable target for the use of cSVF (isolated Stromal Vascular Fraction cells) to help mitigate damaged gas exchange areas of the involved lung tissues, based on positive clinical experiences in COPD and IFL disease patients,” Alexander said.
According to SDARTs CEO, Marcille Pilkington, the article “represents a promising treatment for these patients. We’ve known that Adipose-derived cSVF promotes repair and regenerative effects in COPD patients. To deploy this treatment in Coronavirus survivors is truly exciting.”
“Unfortunately, we had to cancel this year’s global conference in San Diego due to the pandemic. But we’ve archived more than three years of conference video content, plus specialized compendiums, master classes and presentations from expert contributors, that will help doctors learn more about the evolving uses of Microfat, Nanofat, and cSVF in regenerative therapies,” noted Pilkington. “All of this is now available online and on-demand.”
“We’re also in the early stage of preparations for the SDARTs 2021 Global Conference in August 2021, where we’ll present the latest in the uses of adipose therapies for COVID-19 as well as therapies for musculoskeletal applications, hair restoration, regenerative aesthetics and breast reconstruction,” he concluded.
Alexander’s newest article detailing the diagnostic and treatment protocol for this groundbreaking clinical trial is scheduled to be published in the next edition of Stem Cell Research on June 25.